

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : Unassigned Confirmation No.: Unassigned
Applicant : Pierre-Etienne CHABRIER DE LASSAUNIERE
Filed : January 18, 2006
Title : USE OF BOTULINUM TOXIN FOR PRODUCING DRUG FOR
 PREVENTING OR TREATING FINAL PHASE OF LUNG
 TROUBLES
TC/Art Unit : Unassigned
Examiner: : Unassigned

Docket No. : 58767.000011
Customer No. : **21967**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.115

Sir,

Please amend the above-captioned application under 37 C.F.R. § 1.115 as set forth below. Applicants respectfully note that this amendment to the specification incorporates the cross-reference to related applications, setting forth the claims for priority, and is provided within the time period set forth in 37 C.F.R. § 1.78. Accordingly, no fees are believed to be required with this preliminary amendment. However, should any additional fees be required for entry of this amendment, the Commissioner is hereby authorized to charge such fees, or credit any overpayment, to Deposit Account No. 50-0206.

Amendments to the specification are presented on page 2 of this paper.

Remarks begin on page 3 of this paper.